Overview
Corporate Profile
Gamida Cell is an advanced cell therapy company committed to finding cures for patients with cancer and other serious diseases. We harness our NAM-enabled technology platform to create therapies with the potential to improve the course of cancer care.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Latest News
View All
Sep 19, 2022
Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies
Read More
Sep 12, 2022
Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting
Read More
Aug 15, 2022
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
Read More
Aug 10, 2022
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
Read More
Aug 08, 2022
Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
Read More
Aug 01, 2022
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
Read More
Jun 13, 2022
Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
Read More
Jun 10, 2022
Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors
Read More
Jun 02, 2022
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
Read More
Jun 01, 2022
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
Read More
Jun 01, 2022
Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
Read More
May 17, 2022
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference
Read More
May 10, 2022
Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
Read More
May 05, 2022
Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022
Read More
May 03, 2022
Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
Read More
Apr 27, 2022
Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
Read More
Apr 26, 2022
Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201
Read More
Apr 25, 2022
Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
Read More
Apr 25, 2022
Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
Read More
Apr 07, 2022
Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference
Read More
Upcoming Events
Recent Events
Corporate Fact Sheet
Corporate Presentation
In the News
September 5, 2022
Source
The Wall Street Transcript
August 16, 2022
Source
Cell & Gene Therapy Insights
December 1, 2021
Source
Life Science Leader
December 1, 2021
Source
Life Science Leader
October 21, 2021
Source
Blood
July 20, 2021
Source
ASH Clinical News
July 16, 2021
Source
GeneTherapyLive
June 23, 2021
Source
Cell & Gene
June 22, 2021
Source
GeneTherapyLive
March 26, 2021
Source
Pharmacy Times
Investor & Media Contact
Heather DiVecchia
Chief of Staff
Gamida Cell Ltd.
IRPR@gamida-cell.com